Johnson & Johnson

Latest Headlines

Latest Headlines

Ex-FDA chief testifies against J&J in Risperdal liability case

Johnson & Johnson knew as early as 2001 that its antipsychotic drug Risperdal could cause boys to grow breasts, former FDA chief David Kessler testified in Philadelphia court Wednesday. That's 5 years before the company added a warning about the side effect to the drug's official label.

Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data

Bayer and Johnson & Johnson have plunked down hundreds of millions to study the anticoagulant Xarelto for one use after another. Armed with more indications than any of its warfarin-alternative rivals, Xarelto now has the biggest share of that market.

J&J employee sniffs out spy camera in unisex bathroom

With all the info that's available online these days, the only place that might feel private is behind closed doors in the bathroom. Not so for some staffers at Johnson & Johnson in New York City, where an employee discovered a pinhole camera hidden inside a unisex bathroom. 

J&J launches new, smaller, more precise vascular stapler for thoracic surgery

Johnson & Johnson chairman and CEO Alex Gorsky only highlighted a handful of upcoming medical devices in the company's recent 2014 earnings call. Notably, one of them was the Echelon Flex Powered Vascular Stapler. J&J subsidiary Ethicon is launching the stapler in the U.S. at The Society of Thoracic Surgeons meeting this week in San Diego, CA

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

Last week opening arguments were made in a case in which Johnson & Johnson is accused of marketing the antipsychotic drug Risperdal for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts like a woman.

Plaintiffs' lawyers dismiss J&J's latest claim as vaginal mesh litigation drags on

In the latest act of the vaginal mesh litigation drama, plaintiffs' lawyers disputed J&J's claims that fishy phone calls recruiting women to file vaginal mesh-related suits are tainting the legal process and deserve further investigation.

J&J, Boston Sci present closing arguments in 10-plus-year legal spat over Guidant

A titanic struggle is nearing its end. Rivals Boston Scientific and Johnson & Johnson are done presenting their arguments in a legal spat involving the disastrous 2005-2006 bidding war and purchase of cardiology player Guidant. The purchase threatens to become an even worse decision for acquirer Boston Scientific, which would owe $7.2 billion if J&J gets its way.

J&J settles the score with over 100 vaginal mesh plaintiffs

One week after Johnson & Johnson said that women were being illegally solicited by unknown callers to sue over the company's transvaginal mesh devices, J&J has agreed to settle more than 100 product liability lawsuits regarding pelvic mesh products sold by its Mentor subsidiary.

J&J forms consortia to accelerate Ebola vaccine development, gets €100M boost from IMI

Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.

Strong dollar plus strong franc equals worries for global Big Pharma

When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.